key: cord-0331267-2xfn6twk authors: Guenther, M.; Haas, M.; Heinemann, V.; Kruger, S.; Westphalen, C. B.; von Bergwelt-Baildon, M.; Mayerle, J.; Werner, J.; Kirchner, T.; Boeck, S.; Ormanns, S. title: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer * translational results from the AIO-PK0104 phase 3 study date: 2020-05-06 journal: nan DOI: 10.1101/2020.05.01.20087668 sha: 18b515ce8094a9b5e075af40135c2523f64c5ddc doc_id: 331267 cord_uid: 2xfn6twk Background: Gram-negative bacteria mediated gemcitabine resistance in pre-clinical models. We determined if intratumoral lipopolysaccharide (LPS) detection by immunohistochemistry is associated with outcome in advanced pancreatic ductal adenocarcinoma (PDAC) treated with gemcitabine and non-gemcitabine containing 1st-line chemotherapy. Methods: We examined LPS on tumor tissue from 130 patients treated within the randomized phase 3 trial AIO-PK0104 and a validation cohort (n=113) from a prospective biomarker study and analyzed the association of LPS detection to patient outcome according to treatment subgroups. Results: In 24% of samples from the AIO-PK0104 study LPS was detected; in LPS-positive patients median OS was 4.4 months, compared to 7.3 months with LPS negative tumors (HR 1.732, p=0.010). A difference in OS was detected in the subgroup of patients treated with 1st-line gemcitabine-based treatment (n=71; HR 2.377, p=0.002), whereas no difference in OS was observed in the non-gemcitabine subgroup (n=59; HR 1.275, p=0.478). Within the validation cohort, the LPS positivity rate was 23%, and LPS detection was correlated with impaired OS in the gemcitabine subgroup (n=94; HR 1.993, p=0.008) whereas no difference in OS was observed in the non-gemcitabine subgroup (n=19; HR 2.596, p=0.219). Conclusions: The detection of intratumoral LPS as a surrogate marker for gram-negative bacterial colonization may serve as a negative predictor for gemcitabine efficacy in advanced PDAC. Clinical trial registry: NCT00440167 was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 6, 2020. The majority of patients with pancreatic ductal adenocarcinoma (PDAC) is diagnosed in an 2 advanced stage, resulting in mortality rates almost equal to incidence rates 1 . Palliative 3 chemotherapy is considered as an international standard of care for these patients; however, 4 relevant predictive biomarkers for rational treatment decisions are still lacking 2 . Increasing 5 evidence indicates a crucial role for the human microbiome in solid malignancies, especially 6 in gastrointestinal tumors which are in close contact to dense microbial colonization 3, 4 . 7 Importantly, intratumoral bacteria have been shown to promote tumorigenesis 5 and to confer 8 resistance to gemcitabine in human adenocarcinoma 6, 7 . As reported recently, intratumoral 9 bacteria can metabolize gemcitabine (2′,2′-difluorodeoxycytidine) into its inactive form 2′,2′-10 difluorodeoxyuridine; in a pre-clinical model, gemcitabine depletion was dependent on the 11 expression of a long isoform of the bacterial enzyme cytidine deaminase (CDD L ) commonly 12 found in gram-negative bacteria 7 . Bacterial lipopolysaccharide is a major component of the 13 cell wall of gram-negative bacteria and can easily be detected by immunohistochemistry 7 . 14 In the present study, we report the results of immunohistochemical detection of intratumoral 15 LPS as a surrogate marker of gram-negative bacterial colonization in the tumor tissue of 243 16 patients with advanced PDAC from two independent study cohorts and the correlation of 17 intratumoral LPS detection to patient outcome according to the applied 1 st -line chemotherapy 18 regimen (gemcitabine vs non-gemcitabine containing). 19 20 21 Patients and tumor samples 23 Archival tumor material was derived from 130 advanced PDAC patients treated within the 24 randomized phase 3 study AIO-PK0104 (NCT00440167), that compared a 1 st -line treatment 25 with gemcitabine + erlotinib versus capecitabine + erlotinib (with the option of a cross-over to 26 the comparator cytotoxic drug in the 2 nd -line setting) 8 . A validation of the LPS results from 27 AIO-PK0104 was performed on 113 patient samples derived from a previously reported 28 prospective biomarker trial 9 , in which the 1 st -line chemotherapy regimens were as follows: 40 29 patients received gemcitabine monotherapy, 29 patients gemcitabine and cisplatin, 10 30 patients gemcitabine and oxaliplatin, 14 gemcitabine and capecitabine, 11 patients single-31 agent capecitabine, 7 patients capecitabine and oxaliplatin, one patient received FOLFOX-6 32 and one patient received gemcitabine and 5-FU. Both studies had approval of the local ethics 33 committee and were conducted according to GCP/ICH. 34 35 36 37 All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.01.20087668 doi: medRxiv preprint LPS immunohistochemistry 1 Intratumoral bacterial LPS was detected immunohistochemically on formalin fixed paraffin 2 embedded (FFPE) tumor material as described previously 10 using a monoclonal mouse anti-3 LPS antibody detecting the core bacterial LPS antigen (clone WN1 222-5, Hycult Biotech, 4 Uden, The Netherlands) at a 1:800 dilution. Tumors from 133 patients were included in a 5 tissue microarray (TMA) as three cores of one mm diameter each (71 samples from the AIO-6 PK0104 cohort, 62 samples from the validation cohort), whereas biopsies from 110 patients 7 were stained as whole mount tissue sections (59 samples from the AIO-PK0104 cohort, 51 8 samples from the validation cohort). Normal human colonic mucosa, which physiologically 9 carries high amounts of gram-negative bacteria and normal human liver tissue, which 10 physiologically may show high amounts of LPS, were used as positive controls in each 11 staining run (suppl. figure S1A and S1B). Of note, normal adjacent pancreatic tissue did not 12 show LPS signals nor unspecific staining in acinar cells (figure S1C). On TMA embedded 13 tumor tissue, cases showing strong signals in at least one TMA core or weak and single 14 signals in at least two cores were evaluated as positive, whereas all others were evaluated 15 as negative. On whole mount tissue sections, the presence of definitive LPS signals 16 throughout the tumor tissue was evaluated as positive, whereas complete absence of signal 17 was evaluated as negative. All slides were read and scored by two researchers (MG, SO), 18 blinded to the patient outcome and discrepant cases were discussed until agreement was 19 reached. Microphotographs were acquired as described previously 10 . 20 In the overall population (n=243) median patient age was 62 years; 145 patients were male. 33 On therapy initiation, 23 patients from the AIO-PK0104 trial and 10 patients from the 34 validation cohort had locally advanced disease, whereas all others had distant metastases. 35 Both cohorts were comparable in terms of patient age, sex, KPS groups as well as tissue 36 sample origin and tissue modality (TMA vs whole slide). In the AIO-PK0104 cohort, we 37 All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.01.20087668 doi: medRxiv preprint detected more locally advanced cases, higher grade tumors and less lung metastases. 1 Related to the trial design, more patients received non-gemcitabine based 1 st -line 2 chemotherapy in the AIO-PK0104 cohort (table S2) Moreover, we found no statistically significant association between LPS detection and patient 19 characteristics such as gender, age group, KPS group or tumor differentiation (table 1) (table 2) . 37 All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 6, 2020. In Cox multivariate regression analyses adjusting for the parameters which were statistically 1 significant prognosticators in univariate analyses (tumor grade, KPS and disease stage at 2 chemotherapy initiation), we confirmed LPS detection as independent negative predictor for 3 both PFS and OS in the gemcitabine 1 st -line chemotherapy subgroup (table 3) . 4 To preclude a potential impact of the imbalance of LPS positivity in metastatic and primary 5 tumor tissue, we compared OS and PFS according to LPS detection in each subgroup and 6 obtained similar results as in the overall cohorts (table S7) pre-clinical data suggesting that intratumoral bacteria mediate tumor resistance to 21 gemcitabine 7 . However, as to our best knowledge, these data have never been clinically 22 validated yet. As gemcitabine is mainly applied in PDAC, we thought to validate the 23 hypotheses from Geller and co-workers on patient samples from our previously conducted 24 clinical trials in advanced PDAC 8, 9 . As both the AIO-PK0104 cohort as well as the validation 25 cohort contained patients treated with 1 st -line gemcitabine and also non-gemcitabine 26 containing chemotherapy, we thought to evaluate a potential predictive role for the 27 occurrence of intratumoral bacteria on gemcitabine efficacy. 28 Unfortunately, no positivity rates of LPS immunohistochemistry were reported in the study by 29 Geller et al., but the rate of 25% LPS positivity in our overall study population was 30 significantly lower than the rate of 76% 'bacterial DNA'-positive PDAC samples reported in 31 their study 7 . However, as their molecular assay detects all kinds of bacteria with superior 32 sensitivity compared to immunohistochemistry and LPS is a cell wall component of gram-33 negative bacteria only, both figures are not directly comparable. One also might expect 34 higher positivity rates examining whole mount primary tumor resection specimens -as 35 performed by Geller and colleagues -compared to biopsy tissue or TMA embedded tumor 36 material. Nevertheless, we precluded a potential bias resulting from tissue modality and 37 All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.01.20087668 doi: medRxiv preprint confirmed the reliability of TMA embedded tissue to detect intratumoral LPS compared to 1 whole mount tissue. Moreover, although our study population consisted of patients with 2 advanced PDAC, where histological confirmation is often performed by a percutaneous 3 biopsy of metastases 9 , we even detected higher positivity rates in metastases than in 4 primary tumors, which was mostly due to more LPS positive liver metastases. However, 5 intratumoral LPS detection remained a potential negative predictor of gemcitabine efficacy 6 irrespective of the tissue origin subgroup. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.01.20087668 doi: medRxiv preprint Nevertheless, based on the results from AIO-PK0104 and the validation cohort, intratumoral 1 bacterial LPS detection in PDAC samples may serve as a novel negative predictive 2 biomarker for gemcitabine efficacy, confirming previous pre-clinical observations. These 3 findings must be validated prospectively and should be addressed in the light that this 4 biomarker also may be modifiable by the use of antibiotics. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.01.20087668 doi: medRxiv preprint Ethics approval and consent to participate 2 In both study cohorts, the local ethics committee approved the use of patient material for 3 translational research purposes (project numbers 554-11 and 401-15). All patients gave 4 written informed consent to participate in their respective study upon study enrollment. This 5 study was performed in accordance with the Declaration of Helsinki. 6 7 Data availability 8 All supplemental data of this manuscript can be found on the journals website. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 6, 2020. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 6, 2020. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 6, 2020. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.01.20087668 doi: medRxiv preprint Median times of overall survival (OS) and progression free survival (PFS) according to 9 intratumoral LPS detection in each subgroup according to tumor tissue origin (primary tumor 10 vs metastatic tissue) as well as corresponding hazard ratios (HR) and 95% confidential 11 intervals (95% CI). was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.01.20087668 doi: medRxiv preprint CA: a cancer journal for 2 clinicians Therapeutic 4 developments in pancreatic cancer: current and future perspectives Tumor 7 microbiome diversity and composition influence pancreatic cancer outcomes The microbiome, 10 cancer, and cancer therapy Gut 12 microbiota promotes tumor growth in mice by modulating immune response Local 15 bacteria affect the efficacy of chemotherapeutic drugs 17 Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic 18 drug gemcitabine Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus 21 erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a 22 randomised phase 3 trial of the Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. 26 British journal of cancer Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma. 29 British journal of cancer Chemotherapy for pancreatic cancer Management 33 and supportive treatment of frail patients with metastatic pancreatic cancer 36 FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer Increased 39 survival in pancreatic cancer with nab-paclitaxel plus gemcitabine